Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785367 | 0.87 | APP (0.54) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL772566 | 0.84 | MAPT (0.78) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL769325 | 0.81 | APP (0.61) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL11011832 | 0.77 | MAPT (0.69) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL11037107 | 0.76 | MAPT (0.68) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL11037807 | 0.76 | APP (0.72) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL13539184 | 0.76 | MAPT (0.68) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL20303360 | 0.76 | FLT3 (0.53) | APPTP53MAPTLMNASMN1; SMN2 | |
| SCHEMBL74730 | 0.76 | MAPT (0.80) | TP53MAPTLMNASMN1; SMN2RAB9A | |
| SCHEMBL10067623 | 0.76 | APP (0.86) | APPTP53MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551963-B2 | Imidazolothiazole compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GRK2, GRK3, GRK4 | APP 4143/4885TP53 905/4885MAPT 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.